# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and lowers the price target from...
Wells Fargo analyst Larry Biegelsen maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from...
Piper Sandler analyst Adam Maeder maintains Inari Medical (NASDAQ:NARI) with a Neutral and lowers the price target from $55 ...
Needham analyst Mike Matson maintains Inari Medical (NASDAQ:NARI) with a Buy and lowers the price target from $72 to $57.
Inari Medical (NASDAQ:NARI) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.1...